Amelioration of circulating lipoprotein profile and proteinuria in a patient with LCAT deficiency due to a novel mutation (Cys74Tyr) in the lid region of LCAT under a fat-restricted diet and ARB treatment

Atherosclerosis. 2013 May;228(1):193-7. doi: 10.1016/j.atherosclerosis.2013.02.034. Epub 2013 Mar 14.

Abstract

Familial lecithin-cholesterol acyltransferase (LCAT) deficiency is a hereditary disease characterized by an abnormal lipid profile, corneal opacity, anemia and progressive renal disease. We report a patient with complete loss of LCAT activity due to a novel lcat gene mutation of Cys74Tyr in the lid region of LCAT protein. Esterification of cholesterol in this patient was disturbed by disruption of a substrate binding loop of Cys50-Cys74 in LCAT protein. She had progressive renal dysfunction, proteinuria, corneal opacity, anemia and an abnormal lipid profile. Her serum lipids showed a significant increase in abnormal lipoproteins at the original position in agarose gel electrophoresis and VLDL-cholesterol, and a severe decrease in serum HDL-cholesterol. Lipoprotein analyzes also revealed the presence of an abnormal midband lipoprotein, and a maturation disturbance of HDL particles. Renal function and proteinuria improved following the adoption of a fat-restricted diet and administration of an angiotensin II receptor blocker. The abnormal lipoproteins also decreased after this treatment.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin II Type 1 Receptor Blockers / therapeutic use*
  • Cholesterol / blood
  • Corneal Opacity / genetics
  • Corneal Opacity / metabolism
  • Diet, Fat-Restricted*
  • Disulfides / metabolism
  • Esterification
  • Female
  • Humans
  • Lecithin Cholesterol Acyltransferase Deficiency* / diet therapy
  • Lecithin Cholesterol Acyltransferase Deficiency* / drug therapy
  • Lecithin Cholesterol Acyltransferase Deficiency* / genetics
  • Lipoproteins / blood
  • Middle Aged
  • Phosphatidylcholine-Sterol O-Acyltransferase / genetics*
  • Phosphatidylcholine-Sterol O-Acyltransferase / metabolism
  • Point Mutation
  • Proteinuria* / diet therapy
  • Proteinuria* / drug therapy
  • Proteinuria* / genetics

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Disulfides
  • Lipoproteins
  • Cholesterol
  • Phosphatidylcholine-Sterol O-Acyltransferase